


**NYSTATIN- nystatin tablet, film coated**  
**AvKARE**

-----  
**Nystatin Tablets USP**

**Rx only**

**DESCRIPTION**

Nystatin, USP is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Its structural formula:



C<sub>47</sub>H<sub>75</sub>NO<sub>17</sub> M.W. 926.13

Nystatin tablets USP contain the inactive ingredients: Corn Starch, Povidone, Compressible Sugar, Microcrystalline Cellulose, Sodium Starch Glycolate, Talc, Magnesium Stearate, Purified Water, and Coloring.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics**

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

## **Microbiology**

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## **INDICATIONS AND USAGE**

Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis.

## **CONTRAINDICATIONS**

Nystatin Tablets are contraindicated in patients with a history of hypersensitivity to any of their components.

## **PRECAUTIONS**

### **General**

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

### **Pregnancy**

Teratogenic Effects

#### *Pregnancy Category C*

Animal reproduction studies have not been conducted with nystatin. It is also not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin should be given to a pregnant woman only if clearly needed.

### **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

## **ADVERSE REACTIONS**

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported (see **PRECAUTIONS, General**).

### **Gastrointestinal**

Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

### **Dermatologic**

Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

### **Other**

Tachycardia, bronchospasm, facial swelling, and nonspecific myalgia have also been rarely reported.

**To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email [drugsafety@avkare.com](mailto:drugsafety@avkare.com); or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## **OVERDOSAGE**

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

## **DOSAGE AND ADMINISTRATION**

The usual therapeutic dosage is one to two tablets (500,000 to 1,000,000 units nystatin) three times daily. Treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

## **HOW SUPPLIED**

Nystatin Tablets USP, 500,000 Units are round, convex, brown, film-coated tablet debossed with 93 on one side and 983 on the reverse and are packaged in bottles of 90 tablets (NDC 42291-651-90).

Store at 20° and 25°C (68° and 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Keep tightly closed.

**KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.**

Manufactured For:

**AvKARE, Inc.**

Pulaski, TN 38478

Mfg. Rev. N 2/2016

AV Rev. 05/18 (P)

**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL**

AvKARE

NDC 42291-651-90

Nystatin

Tablets USP

500,000 units (oral)

90 Tablets Rx Only

**Each film-coated tablet contains** 500,000  
units nystatin, USP.

**Usual Dosage:** See package insert for full  
prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP  
Controlled Room Temperature].

KEEP TIGHTLY CLOSED.

**Dispense** in a tight, light-resistant container as  
defined in the USP, with a child-resistant  
closure (as required).

**KEEP THIS AND ALL MEDICATIONS OUT OF  
THE REACH OF CHILDREN.**

Manufactured for:

**AvKARE, Inc.**

Pulaski, TN 38478

Mfg. Rev. L 02/16 AV Rev. 05/18 (P)



**Nystatin  
Tablets USP**

**500,000 units (oral)**

**90 Tablets Rx Only**

Each film-coated tablet contains 500,000 units nystatin, USP.

**Usual Dosage:** See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

**KEEP TIGHTLY CLOSED.**

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

**KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.**

Manufactured for:  
**AvKARE, Inc.**  
 Pulaski, TN 38478

Mfg. Rev. L 02/16 AV Rev. 05/18 (P)



**NYSTATIN**  
 nystatin tablet, film coated

Product Information			
<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:42291-651(NDC:0093-0983)
<b>Route of Administration</b>	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	500000 [USP'U]

Inactive Ingredients	
Ingredient Name	Strength
STARCH, CORN (UNII: O8232NY3SJ)	
POVIDONE K29/32 (UNII: 390RMW2PEQ)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
TALC (UNII: 7SEV7J4R1U)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
WATER (UNII: 059QF0KO0R)	
ISOPROPYL ALCOHOL (UNII: ND2M416302)	

Product Characteristics			
<b>Color</b>	brown	<b>Score</b>	no score
<b>Shape</b>	ROUND	<b>Size</b>	10mm
<b>Flavor</b>		<b>Imprint Code</b>	93;983
<b>Contains</b>			

**Packaging**

Marketing Start      Marketing End

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42291-651-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	01/20/2014	
<b>Marketing Information</b>				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA062506	01/20/2014		

**Labeler - AvKARE (796560394)**

Revised: 1/2024

AvKARE